Advertisement

Microchimica Acta

, Volume 183, Issue 12, pp 3321–3327 | Cite as

Porous silicon microarray for simultaneous fluorometric immunoassay of the biomarkers prostate-specific antigen and human glandular kallikrein 2

  • SangWook LeeEmail author
  • Kazuo Hosokawa
  • Soyoun Kim
  • Ok Chan Jeong
  • Hans Lilja
  • Thomas Laurell
  • Mizuo Maeda
Short Communication

Abstract

The authors have developed a porous silicon (P-Si) based duplex antibody microarray platform for simultaneous quantitation of the biomarkers prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in serum. Pore size-controlled P-Si surfaces have an extremely enlarged surface area that enables high-density immobilization of fluorescently labeled antibodies by physical adsorption. Automated microarraying of the antibodies provides a fast and reproducible duplex format of antibody arrays on the P-Si chips placed in the wells of a microtiter plate. The assay platform showed a 100 fg·mL−1 limit of detection for both PSA and hK2, and a dynamic range that extends over five orders of magnitude. After optimization of the density of both capture antibodies, neither the PSA nor the hK2 array showed cross-sensitivity to non-target proteins or other plasma proteins. The microarray was evaluated by titration of PSA and hK2, respectively, in the same serum samples. In our perception, this highly sensitive and selective platform holds promise for improved detection of tumor markers in an early diagnostic stage, but also to monitor the recurrence of prostate cancer.

Graphical Abstract

A porous silicon microarray platform is presented for simultaneous detection of biomarkers prostate specific antigen and human glandular kallikrein 2 in human blood sample. The platform shows highly sensitive and selective biomarker detection features.

Keywords

Duplex antibody microarray PSA hK2 Silicon anodization Prostate cancer Serum analysis 

Notes

Acknowledgments

This study was partly supported by RIKEN FPR program and JSPS KAKENHI Grant Number 25350581. This project is also supported by Korea Ministry of Environment as “EI project” (ERL E211-41003-0007-0).

Compliance with ethical standards

The author(s) declare that they have no competing interests.

Supplementary material

604_2016_1986_MOESM1_ESM.docx (5.2 mb)
ESM 1 (DOCX 5279 kb)

References

  1. 1.
    Ekins RP (1989) Multi-analyte immunoassay. J Pharm Biomed Anal 7:155–168CrossRefGoogle Scholar
  2. 2.
    Ling MM, Ricks C, Lea PI (2007) Multiplexing molecular diagnostics and immunoassays using emerging microarray technologies. Expert Rev Mol Diagn 7:87–98CrossRefGoogle Scholar
  3. 3.
    Kingsmore SF (2006) Multiplexed protein measurement: technologies and applications of protein and antibody arrays. Nat Rev Drug Discov 5:310–321CrossRefGoogle Scholar
  4. 4.
    Ellington A, Kullo IJ, Bailey KR, Klee G (2010) Antibody-based protein multiplex platforms: technical and operational challenges. Clin Chem 56:186–193CrossRefGoogle Scholar
  5. 5.
    Horn S, Lueking A, Murphy D, Staudt A, Gutjahr C, Schulte K, König A, Landsberger M, Lehrach H, Felix SB, Cahill DJ (2006) Profiling humoral autoimmune repertoire of dilated cardiomyopathy (DCM) patients and development of a disease-associated protein chip. Proteomics 6:605–613CrossRefGoogle Scholar
  6. 6.
    Ptacek J, Devgan G, Michaud G, Zhu H, Zhu X, Fasolo J, Guo H, Jona G, Breitkreutz A, Sopko R, McCartney RR, Schmidt MC, Rachidi N, Lee S, Mah AS, Meng L, Stark M, Stern DF, De Virgilio C, Tyers M, Andrews B, Gerstein M, Schweitzer B, Predki PF, Snyder M (2005) Global analysis of protein phosphorylation in yeast. Nature 438:679–684CrossRefGoogle Scholar
  7. 7.
    Miller MB, Tang Y (2009) Basic concepts of microarrays and potential applications in clinical microbiology. Clin Microbiol Rev 22:611–633CrossRefGoogle Scholar
  8. 8.
    Diamondis EP, Yousef GM (2002) Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem 48:1198–1205Google Scholar
  9. 9.
    Pampalakis G, Sotiropoulou G (2007) Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim Biophys Acta 1776:22–31Google Scholar
  10. 10.
    Vickers A, Cronin A, Roobol M, Savage C, Peltola M, Pettersson K, Scardino F, Schroder PT, Lilja H (2010) Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol 28:2493–2498CrossRefGoogle Scholar
  11. 11.
    Tewari A, Raman JD, Chang P, Rao S, Divine G, Menon M (2006) Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy). Urology 68:1268–1274CrossRefGoogle Scholar
  12. 12.
    Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG (2004) Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 100:1397–1405CrossRefGoogle Scholar
  13. 13.
    Andriole GL, Levin D, Crawford ED, Gelmann E, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlian G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK (2005) Prostate cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 97:433–438CrossRefGoogle Scholar
  14. 14.
    Lilja H, Ulmert D, Vickers AJ (2008) Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 8:268–278CrossRefGoogle Scholar
  15. 15.
    Recker F, Maciej FR, Kwiatkowski K, Piironen T, Pettersson K, Lümmen G, Wernli M, Wiefelspütz J, Graber SF, Goepel M, Huber A, Tscholl R (1998) The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. Cancer 83:2540–2547CrossRefGoogle Scholar
  16. 16.
    Steuber T, Vickers AJ, Serio AM, Vaisanen V, Haese A, Pettersson K, Eastham JA, Scardino PT, Huland H, Lilja H (2007) Prostate specific kallikrein-related peptidases and their relation to prostate cancer biology and detection; established relevance and emerging roles. Clin Chem 53:233–240CrossRefGoogle Scholar
  17. 17.
    Henttu P, Lukkarinen O, Vihko P (1990) Expression of the gene coding for human prostate-specific antigen and related hGK-1 in benign and malignant tumors of the human prostate. Int J Cancer 45:654–660CrossRefGoogle Scholar
  18. 18.
    van Gils M, Stenman UH, Schalken JA, Schröder FH, Luider TM, Lilja H, Bjartell A, Hamdy, Pettersson Bischoff K, Takalo R, Nilsson O, Mulders P, Bangma C (2005) Innovations in serum and urine markers in prostate cancer current European research in the P-mark project. Eur Urol 48:1031–1041CrossRefGoogle Scholar
  19. 19.
    Kumar A, Mikolajczyk SD, Goel AS, Millar LS, Saedi MS (1997) Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 57:3111–3114Google Scholar
  20. 20.
    Lilja H, Christensson A, Dahlén U, Matikainen MT, Nilsson O, Pettersson K, Lövgren T (1991) Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 37:1618–1625Google Scholar
  21. 21.
    Zhang W, Finne P, Leinonen J, Vesalainen S, Nordling S, Stenman U (1991) Measurement of the complex between prostate-specific antigen and α1-protease inhibitor in serum. Clin Chem 45:814–821Google Scholar
  22. 22.
    Jung K, Elgeti U, Lein M, Brux B, Sinha P, Rudolph B, Hauptmann S, Schnorr D, Loening SA (2000) Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer. Clin Chem 46:55–62Google Scholar
  23. 23.
    Roddam AW, Duffy MJ, Hamdy FC, Ward AW, Patnick J, Price CP, Rimmer J, Sturgeon C, White P, Allen NE (2005) Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2–10 ng/ml: systematic review and meta-analysis. Eur Urol 48:386–399CrossRefGoogle Scholar
  24. 24.
    Järås K, Adler B, Tojo A, Malm J, Marko-Varga G, Lilja H, Laurell T (2012) PSA quantification of 80 plasma samples from the clinical routine using antibody mircoarrays. Clin Chim Acta 414:76–84CrossRefGoogle Scholar
  25. 25.
    Liu D, Huang X, Wang Z, Jin A, Sun X, Zhu L, Wang F, Ma Y, Niu G, Walker A (2013) Chen X gold nanoparticle-based activatable probe for sensing ultralow levels of prostate-specific antigen. ACS Nano 7:5568–5576CrossRefGoogle Scholar
  26. 26.
    Thaxton C, Elghanian R, Thomas A, Stoeva S, Lee J, Smith N, Schaeffer A, Klocker H, Horninger W, Bartsch G, Mirkin C (2009) Nanoparticle-based bio-barcode assay redefines “undetectable” PSA and biochemical recurrence after radical prostatectomy. PNAS 106:18437–18442CrossRefGoogle Scholar
  27. 27.
    Kim SH, Iwai S, Araki S, Sakakihara S, Iino R, Noji H (2012) Large-scale femtoliter droplet array for digital counting of single biomolecules. Lab Chip 12:4986–4991CrossRefGoogle Scholar
  28. 28.
    Wilson D, Hanlon D, Provuncher G, Chang L, Song L, Patel P, Ferrell E, Lepor H, Partin A, Chan D, Sokoll L, Cheli C, Thiel R, Fournier D, Duffy D (2011) Fifth-generation digital immunoassay for prostate-specific antigen by single molecule array technology. Clin Chem 57:1712–1721CrossRefGoogle Scholar
  29. 29.
    Lee SW, Kim S, Malm J, Jeong OC, Lilja H, Laurell T (2013) Improved porous silicon (P-Si) microarray based PSA (prostate specific antigen) immunoassay by optimized surface density of the capture antibody. Anal Chim Acta 796:108–114CrossRefGoogle Scholar
  30. 30.
    Uludag Y, Köktürk G (2015) Determination of prostate-specific antigen in serum samples using gold nanoparticle based amplification and lab-on-a-chip based amperometric detection. Microchim Acta 182:1685–1691CrossRefGoogle Scholar
  31. 31.
    Sun XC, Lei C, Guo L, Zhou Y (2016) Sandwich immunoassay for the prostate specific antigen using a micro-fluxgate and magnetic bead labels. Microchim Acta 183:2385–2393CrossRefGoogle Scholar
  32. 32.
    Stephan C, Jung K, Nakamura T, Yousef GM, Kristiansen G, Diamond EP (2006) Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. Int J Urol 13:238–243CrossRefGoogle Scholar
  33. 33.
    Vaisanen V, Eriksson S, Ivaska KK, Lilja H, Nurmi M, Pettersson K (2004) Development of sensitive immunoassays for free and total human glandular kallikrein 2. Clin Chem 50:1607–1617CrossRefGoogle Scholar
  34. 34.
    Ressine A, Ekström S, Marko-Varga G, Laurell T (2003) Macro-/nanoporous silicon as a support for high-performance protein microarrays. Anal Chem 75:6968–6974CrossRefGoogle Scholar
  35. 35.
    Lee SW, Hosokawa K, Laurell T, Kim S, Maeda M (2015) A highly sensitive porous silicon (P-Si)-based human kallikrein 2 (hK2) immunoassay platform toward accurate diagnosis of prostate cancer. Sensors 15:11972–11987CrossRefGoogle Scholar
  36. 36.
    Jongho P, Yasuko Y, Takeshi H (2016) Fabrication of p-type porous silicon using double tank electrochemical cell with halogen and LED light sources. Sensors Actuators B 5:136–143Google Scholar

Copyright information

© Springer-Verlag Wien 2016

Authors and Affiliations

  • SangWook Lee
    • 1
    • 2
    Email author
  • Kazuo Hosokawa
    • 1
  • Soyoun Kim
    • 3
  • Ok Chan Jeong
    • 4
  • Hans Lilja
    • 5
    • 6
    • 7
    • 8
  • Thomas Laurell
    • 3
    • 9
  • Mizuo Maeda
    • 1
  1. 1.Bioengineering LaboratoryRIKENSaitamaJapan
  2. 2.Department of ChemistryThe University of TokyoTokyoJapan
  3. 3.Department of Biomedical EngineeringDongguk UniversitySeoulSouth Korea
  4. 4.Department of Mechanical EngineeringInje UniversityGimhae-siSouth Korea
  5. 5.Department of Translational Medicine, Lund UniversitySkåne University Hospital in MalmöMalmöSweden
  6. 6.Departments of Laboratory Medicine, Surgery (Urology), and Medicine (GU Oncology)Memorial Sloan-Kettering Cancer CenterNew YorkUSA
  7. 7.Institute for Biosciences and Medical TechnologyUniversity of TampereTampereFinland
  8. 8.Nuffield Department of Surgical SciencesUniversity of OxfordOxfordUK
  9. 9.Department of Biomedical EngineeringLund UniversityLundSweden

Personalised recommendations